Primary Sjögren syndrome: An update on current pharmacotherapy options and future directions

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 3, 2013, Pages 279-289

  Brito Zerón, Pilar ^a   Sisó Almirall, Antoni ^b   Bové, Albert ^a   Kostov, Belchin A ^b   Ramos Casals, Manuel ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Belimumab; Rituximab; Sj gren syndrome; Therapy

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; ANTIMALARIAL AGENT; AZATHIOPRINE; BROMHEXINE; CEVIMELINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIQUAFOSOL; DOXYCYCLINE; FLUOROMETHOLONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MIZORIBINE; MUSCARINIC AGENT; NIZATIDINE; PENICILLAMINE; PILOCARPINE; PRASTERONE; PREDNISONE; REBAMIPIDE; THALIDOMIDE; UNINDEXED DRUG; ZIDOVUDINE;

APPETITE; CARDIOVASCULAR RISK; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FIBROMYALGIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS SICCA; PLASMAPHERESIS; REVIEW; SALIVATION; SIDE EFFECT; SJOEGREN SYNDROME; WEIGHT GAIN; XEROSTOMIA;

CYCLOSPORINE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; KERATOCONJUNCTIVITIS SICCA; MOLECULAR TARGETED THERAPY; OPHTHALMIC SOLUTIONS; SALIVA, ARTIFICIAL; SJOGREN'S SYNDROME;

EID: 84873336848     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.767333     Document Type: Review

References (96)

1. Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X. Primary Sjogren syndrome. BMJ 2012;344:e3821
2. Fox RI. Sjogren's syndrome. Lancet 2005;366:321-31
3. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 2004;164:1275-84 (Pubitemid 38828877)
4. Ramos-Casals M, Brito-Zeron P, Bove A, Siso A. Sjogren's syndrome: Beyond sicca involvement. In: Khamashta MA, Ramos-Casals M, editors. Autoimmune diseases. Acute and complex situations. Springer-Verlag; London: 2011. p. 45-66
5. Theander E, Baecklund E. Cancer. In: Ramos-Casals M, Stone JH, Moutsopoulos HM, editors. Sjogren syndrome: Diagnosis and therapeutics. Springer; London: 2012. p. 477-92
6. Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjogren's syndrome. Nat Rev Rheumatol 2012;8:399-411
7. Coca A, Sanz I. Updates on B-Cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol 2012;24:451-6
8. Westhoff G, Dorner T, Zink A. Fatigue and depression predict physician visits and work disability in women with primary Sjogren's syndrome: Results from a cohort study. Rheumatology (Oxford) 2012;51:262-9
9. Belenguer R, Ramos-Casals M, Brito-Zeron P, et al. Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2005;23:351-6 (Pubitemid 40823543)
10. Ibn Yacoub Y, Rostom S, Laatiris A, Hajjaj-Hassouni N. Primary Sjogren's syndrome in Moroccan patients: Characteristics, fatigue and quality of life. Rheumatol Int 2012;32:2637-43
11. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjogren syndrome: A systematic review. JAMA 2010;304:452-60
12. Ramos-Casals M, Cervera R, Yague J, et al. Cryoglobulinemia in primary Sjogren's syndrome: Prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 1998;28:200-5 (Pubitemid 28563932)
13. Broadley KJ, Kelly DR. Muscarinic receptor agonists and antagonists. Molecules 2001;6:142-93 (Pubitemid 38990156)
14. Zoukhri D, Kublin CL. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjogren's syndrome. Invest Ophthalmol Vis Sci 2001;42:925-32 (Pubitemid 32289786)
15. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjogren's syndrome. Clin Immunol 2001;101:249-63
16. Wiseman LR, Faulds D. Oral pilocarpine: A review of its pharmacological properties and clinical potential in xerostomia. Drugs 1995;49:143-55
17. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: A randomized, placebo-Controlled, fixed-Dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999;159:174-81 (Pubitemid 29055106)
18. Papas AS, Sherrer YS, Charney M, et al. Successful treatment of dry mouth and dry eye symptoms in Sjogren's syndrome patients with oral pilocarpine: A randomized, placebo-Controlled, dose-Adjustment study. J Clin Rheumatol 2004;10(4):169-77 (Pubitemid 39079593)
19. Segal M, Fisher A. AF102B, a muscarinic M1 receptor agonist, mimics some effects of acetylcholine on neurons of rat hippocampus slices. Eur J Pharmacol 1992;220:103-6
20. Fox RI, Petrone D, Condemi J, et al. Randomized, placebo-Controlled trial of SNI-2011, a novel M3 muscarinic receptor agonist, for the treatment of Sjogren's syndrome (abstract). Arthritis Rheum 1998;41(Suppl):S288
21. Ramos-Casals M, Khamashta MA. Connective tissue disease: Trial of SLE therapies in real-world settings. Nat Rev Rheumatol 2012;8:128-30
22. Moutsopoulos HM, Balow JE, Lawley TJ, et al. Immune complex glomerulonephritis in sicca syndrome. Am J Med 1978;64:955-60 (Pubitemid 8358587)
23. Fox PC, Datiles M, Atkinson JC, et al. Prednisone and piroxicam for treatment of primary Sjogren's syndrome. Clin Exp Rheumatol 1993;11:149-56 (Pubitemid 23155983)
24. Ramos-Casals M, Brito-Zeron P, Siso A, et al. High prevalence of serum metabolic alterations in primary Sjogren's syndrome: Influence on clinical and immunological expression. J Rheumatol 2007;34:754-61 (Pubitemid 46641382)
25. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999;106:811-16 (Pubitemid 30194327)
26. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis 2010;69:20-8
27. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 2011;7:718-29
28. Heaton JM. Antimalarials in treatment of Sjogren's syndrome. Br Med J 1959;1:1512-13
29. Emmungil H, Kalfa M, Zihni FY, et al. Interstitial cystitis: A rare manifestation of primary Sjogren's syndrome, successfully treated with low dose cyclosporine. Rheumatol Int 2012;32:1215-18
30. Shibata S, Ubara Y, Sawa N, et al. Severe interstitial cystitis associated with Sjogren's syndrome. Intern Med 2004;43:248-52 (Pubitemid 38489122)
31. Ogasawara H, Sekiya M, Murashima A, et al. Very low-Dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjogren's syndrome. Clin Rheumatol 1998;17:160-2 (Pubitemid 28253178)
32. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease: CsA Phase 3 Study Group. Ophthalmology 2000;107:631-9 (Pubitemid 30191329)
33. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005;112:1790-4 (Pubitemid 41400017)
34. Ballow M. The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011;127:315-23
35. Rist S, Sellam J, Hachulla E, et al. Club Rhumatismes et Inflammation. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjogren's syndrome: A national multicentric retrospective study. Arthritis Care Res (Hoboken) 2011;63:1339-44
36. Brito-Zeron P, Akasbi M, Bosch X, et al. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2012; [Epub ahead of print
37. Unal-Cevik I, Onal MZ, Odabasi Z, Tan E. IVIG- responsive multiple cranial neuropathy: A pharyngo-facial variant of Guillain-Barre syndrome. Acta Neurol Belg 2009;109:317-21
38. Rajabally YA, Seow H, Abbott RJ. Immunoglobulin-responsive dysautonomia in Sjogren's syndrome. J Neurol 2007;254:674-5
39. Canhao H, Fonseca JE, Rosa A. Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjogren's syndrome. J Rheumatol 2000;27:1102-3 (Pubitemid 30389777)
40. Dupond JL, Gil H, de Wazieres B. Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjogren's syndrome. Am J Med 1999;106:125 (Pubitemid 29077154)
41. Mochizuki H, Kamakura K, Masaki T, et al. Motor dominant neuropathy in Sjogren's syndrome: Report of two cases. Intern Med 2002;41:142-6 (Pubitemid 34223719)
42. Friedman J, Klepfish A, Miller EB, et al. Agranulocytosis in Sjogren's syndrome: Two case reports and analysis of 11 additional reported cases. Semin Arthritis Rheum 2002;31:338-45 (Pubitemid 34415258)
43. Zeuner RA, Schroeder JO, Schroder F, Euler HH. Successful application of high dose intravenous immunoglobulins in Sjogren's syndrome associated arthritis. Ann Rheum Dis 1995;54:936
44. Pisoni CN, Brucato A, Ruffatti A, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum 2010;62:1147-52
45. Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-Label clinical trial. Arthritis Rheum 2010;62:1138-4646
46. Yamashita H, Takahashi Y, Kaneko H, et al. Thrombotic thrombocytopenic purpura with an autoantibody to ADAMTS13 complicating Sjogren's syndrome: Two cases and a literature review. Mod Rheumatol 2012; [Epub ahead of print
47. Simon JA, Lazo-Langner A, Duarte-Rojo A, et al. Serum hyperviscosity syndrome responding to therapeutic plasmapheresis in a patient with primary Sjogren's syndrome. J Clin Apher 2002;17:44-6
48. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjogren's syndrome with low-Dose human interferon alfa administered by the oromucosal route: Combined phase III results. Arthritis Rheum 2003;49:585-93 (Pubitemid 36988314)
49. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-Dose oral IFN-Alpha for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 1998;18:255-62 (Pubitemid 28176009)
50. Khurshudian AV. A pilot study to test the efficacy of oral administration of interferon-Alpha lozenges to patients with Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:38-44 (Pubitemid 36886720)
51. Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sjogren's syndrome: A pilot study. Arthritis Rheum 2001;44:2371-5 (Pubitemid 32977506)
52. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome: Results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6 (Pubitemid 38488821)
53. Zandbelt MM, de Wilde P, van Damme P, et al. EtanercePTin the treatment of patients with primary Sjogren's syndrome: A pilot study. J Rheumatol 2004;31:96-101 (Pubitemid 38067529)
54. Sankar V, Brennan MT, Kok MR, et al. EtanercePTin Sjogren's syndrome: A twelve-week randomized, double-blind, placebo-Controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5 (Pubitemid 38930815)
55. Ramos-Casals M, Brito-Zeron P. Emerging biological therapies in primary Sjogren's syndrome. Rheumatology (Oxford) 2007;46:1389-96 (Pubitemid 47317084)
56. Ramos-Casals M, Sanz I, Bosch X, et al. B-Cell-Depleting therapy in systemic lupus erythematosus. Am J Med 2012;125:327-36
57. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: An open-Label phase I/II study. Arthritis Res Ther 2006;8(4):R129
58. Meijer J, Meiners P, Vissink A, et al. Effective rituximab treatment in primary Sjogren's syndrome: A randomised, double-blind, placebo-Controlled trial. Arthritis Rheum 2010;62:960-8
59. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: Results of a randomised, double-blind, placebo-Controlled pilot study. Ann Rheum Dis 2008;67:1541-4
60. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007;57:310-17 (Pubitemid 47164095)
61. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: An open-Label phase II study. Arthritis Rheum 2005;52:2740-50 (Pubitemid 41369102)
62. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007;66:351-7 (Pubitemid 46579637)
63. Gottenberg JE, Guillevin L, Lambotte O, et al. Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20 (Pubitemid 40733918)
64. Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: Results from the AIR registry. Ann Rheum Dis 2012;71:84-7
65. Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. BIOGEAS Study Group. Off-Label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010;28:468-76
66. Vasil'ev VI, Logvinenko OA, Kokosadze NV, et al. First experience with the application of rituximab for the treatment of patients with Sjogren's syndrome and disease. Vestn Ross Akad Med Nauk 2009;2:3-10
67. Pollard RP, Pijpe J, Bootsma H, et al. Treatment of mucosa-Associated lymphoid tissue lymphoma in Sjogren's syndrome: A retrospective clinical study. J Rheumatol 2011;38:2198-208
68. Mekinian A, Ravaud P, Larroche C, et al. Club Rhumatismes et Inflammation. Rituximab in central nervous system manifestations of patients with primary Sjogren's syndrome: Results from the AIR registry. Clin Exp Rheumatol 2012;30:208-12
69. Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: Results from the AIR registry. Ann Rheum Dis 2012;71:84-7
70. Voulgarelis M, Ziakas PD, Papageorgiou A, et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine (Baltimore) 2012;91:1-9
71. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Tolerance and efficacy of rituximab in primary Sjogren syndrome: Final results of a randomized controlled trial. Arthritis Rheum 2012;64(Suppl):S1079
72. Toumeh A, Josh N, Narwal R, Assaly R. Refractory thrombotic thrombocytopenic purpura associated with primary sjogren syndrome treated with rituximab: A case report. Am J Ther 2012; [Epub ahead of print
73. Zhou L, Xin XF, Wu HX. The efficacy and safety of low-Dose rituximab in treatment of primary Sjogren's syndrome with thrombocytopenia. Zhonghua Nei Ke Za Zhi 2012;51:37-41
74. Uraoka Y, Tanigawa T, Watanabe K, et al. Complete remission of protein-Losing gastroenteropathy associated with Sjogren's syndrome by B cell-Targeted therapy with rituximab. Am J Gastroenterol 2012;107:1266-8
75. Swartz MA, Vivino FB. Dramatic reversal of lymphocytic interstitial pneumonitis in Sjogren's syndrome with rituximab. J Clin Rheumatol 2011;17:454
76. Rueda JC, Duarte-Rey C, Casas N. Successful treatment of relapsing autoinmune pancreatitis in primary Sjogren's syndrome with rituximab: Report of a case and review of the literature. Rheumatol Int 2009;29:1481-5
77. Sanchez-Cano D, Callejas-Rubio JL, Lara-Jimenez MA, et al. Successful use of rituximab in acquired C1 inhibitor deficiency secondary to Sjogren's syndrome. Lupus 2008;17:228-9 (Pubitemid 351588947)
78. Zapata LF, Agudelo LM, Paulo JD, Pineda R. Sjogren keratoconjunctivitis sicca treated with rituximab. Cornea 2007;26:886-7 (Pubitemid 47220569)
79. Seve P, Gachon E, Petiot P, et al. Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjogren's syndrome. Rheumatol Int 2007;28:175-7 (Pubitemid 350105864)
80. Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren's syndrome with rituximab. Scand J Rheumatol 2006;35:323-5 (Pubitemid 44181188)
81. Ahmadi-Simab K, Lamprecht P, Nolle B, et al. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005;64:1087-8 (Pubitemid 40909530)
82. Seror R, Ravaud P, Bowman S, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI): Development of a consensus systemic disease activity index in primary Sjogren's syndrome. Ann Rheum Dis 2010;62:551-8
83. Seror R, Ravaud P, Mariette X, et al. EULAR Sjogren's Task Force. EULAR Sjogren's syndrome patient reported index (ESSPRI): Development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis 2011;70:968-72
84. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab. Ann Rheum Dis 2012;71:1297-302
85. Engel P, Gomez-Puerta JA, Ramos-Casals M, et al. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011;63:127-56
86. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009;119:1066-73
87. Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2012; [Epub ahead of print
88. Youinou P, Saraux A, Pers JO. B-Lymphocytes govern the pathogenesis of Sjogren's syndrome. Curr Pharm Biotechnol 2012;13:2071-7
89. Mariette X, Gottenberg JE. Pathogenesis of Sjogren's syndrome and therapeutic consequences. Curr Opin Rheumatol 2010;22:471-7
90. Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-Cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2012; [Epub ahead of print
91. Ramos-Casals M. The B-Lymphocyte stimulator connection in Sjogren's syndrome. Rheumatology (Oxford) 2012; Epub ahead of print
92. Mariette X, Quartuccio L, Seror R, et al. Results of the BELISS study, the first open phase 2 study of belimumab in primary Sjogren syndrome. Arthritis Rheum 2012;64(Suppl):S1079-80
93. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010;6:326-37
94. Chen YT, Lazarev S, Bahrami AF, et al. Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjogren's syndrome. Lab Invest 2012;92:556-70
95. Chen YT, Nikulina K, Lazarev S, et al. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjogren's syndrome. Am J Pathol 2010;177:1333-43
96. Norheim KB, Harboe E, Gøransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome-A double blind, randomised clinical trial. LoS ONE 2012;7:e30123